Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Biomarkers are strategic assets for biopharma companies, significantly improving the success rate of clinical trials1. Yet, discovering them often feels like navigating through a blizzard of unstructured information, searching for the one true signal that can guide the way. While laboratory automation has eased benchwork, the real storm rages in the data, obscuring access to… The post Finding signals in the storm: Automation in biomarker discovery appeared first on Drug Discovery and Deve...| Drug Discovery and Development
Healthcare is one of the largest sources of “big data,” accounting for upwards of 30% of all data produced globally.1 Early on, the potential benefits of this data for healthcare outcomes were immediately evident. As that promise has begun to materialize, with the advent of AI and machine learning, real signals of improvement in therapeutic… The post Early-phase study design considerations for long-term follow-up in vaccine clinical trials appeared first on Drug Discovery and Development.| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved zoliflodacin for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Labcorp rolls out new NGS panels, HRD testing, and a Leica-Proscia digital pathology platform to accelerate biomarker screening.| Drug Discovery and Development